Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) reported publication in npj Precision Oncology of a study validating Caris AI Insights for first-line treatment selection in pancreatic cancer. The AI-driven molecular signature used large clinico-genomic datasets to predict benefit from FOLFIRINOX versus gemcitabine plus nab-paclitaxel (gem/nab-p).
In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX had a median overall survival of 16.0 months on FOLFIRINOX versus 9.9 months on gem/nab-p. About half of study patients had received a different first-line regimen than the model would have recommended, suggesting potential to improve survival and reduce toxicity through biologically informed choices.
The pancreatic AI signature is integrated into the Caris Molecular Tumor Board Report, generated from whole exome and whole transcriptome sequencing via the MI Cancer Seek assay. According to Caris Life Sciences, MI Cancer Seek received FDA approval in November 2024 as the first simultaneous WES/WTS-based assay with companion diagnostic indications for solid tumors.
Positive
- Median overall survival benefit: standard molecular risk patients predicted for FOLFIRINOX had 16.0 vs 9.9 months on gem/nab-p in the testing cohort
- FDA-approved MI Cancer Seek assay enables simultaneous whole exome and whole transcriptome sequencing with companion diagnostic indications for solid tumors since November 2024
Negative
- None.
News Explained
The study is published; the pancreatic AI signature is available only to Caris customers, upon request and at no additional cost when they order MI Cancer Seek, and the company says it cannot be achieved through small panels.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | AI test launch | Positive | +1.4% | Launched AI test predicting early and late distant recurrence risk in breast cancer |
| Apr 29 | AI study validation | Positive | -3.6% | Published validation of AI signature predicting MGMT methylation and temozolomide benefit |
| Apr 08 | AI treatment guidance | Positive | +4.0% | Introduced AI signature to guide chemotherapy addition in PD-L1-high NSCLC |
| Mar 26 | AI risk signatures | Positive | -1.2% | Added AI signatures predicting brain metastasis risk in breast and lung cancer |
| Mar 16 | AI resistance signature | Positive | +5.0% | Introduced AI signature predicting early platinum resistance in ovarian cancer |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-tagged announcements produced mixed reactions, with three aligned events and two divergences.
Key Terms
pdac medical
folfirinox medical
companion diagnostic regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels
The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX achieved substantially longer median overall survival when treated with FOLFIRINOX rather than gemcitabine plus nab-paclitaxel (gem/nab-p) (16.0 vs 9.9 months). Approximately half of the patients in the study received a different first-line therapy than the model would have recommended, highlighting the potential opportunity for more biologically informed treatment selection to improve survival and reduce toxicity.
The Caris AI Insights signature for pancreatic cancer is included in the Caris Molecular Tumor Board Report. This report, built using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) data, is available upon request at no additional cost when ordering MI Cancer Seek®. Caris AI Insights deliver clinically relevant findings across all tumor types, with disease-specific algorithms to support treatment decision-making in colon, breast, ovarian, pancreatic and lung cancer.
For patients with advanced pancreatic ductal adenocarcinoma (PDAC), first-line therapy options include FOLFIRINOX, gem/nab-p, and NALIRIFOX. The study focused on the first two of these regimens, both of which can extend survival but can also exact a significant physical toll on the patient. Despite differences in toxicity and intensity, clinical judgments about treatment selection are still not sufficiently guided by tumor biology. Currently, clinicians must make the call without a widely adopted biomarker to guide them. As a result, some patients endure unnecessary side effects for limited benefit, while others may never receive the intensity of therapy their disease demands.
"For too long, pancreatic cancer treatment decisions have forced clinicians to choose between toxicity and uncertainty," said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. "Pancreatic AI shows that tumor biology can help guide that decision, identifying patients who may not need the most aggressive therapy, while also flagging those who may derive greater benefit from aggressive treatment. This is about using data and AI to move beyond trial-and-error and toward more precise care from the very first line of treatment."
Rather than relying on individual biomarkers, the pancreatic signature applies machine learning techniques to identify complex molecular patterns associated with real-world treatment benefit. The validation study leveraged Caris' large-scale clinico-genomic datasets, linking comprehensive molecular data with treatment outcomes across thousands of patients. Clinicians are provided with two results: risk stratification to categorize patients as standard or high molecular risk and guidance to help inform selection between FOLFIRINOX and gem/nab-p. The model identifies a meaningful subset of patients who may achieve similar or greater benefit from gem/nab-p, while also flagging patients who are more likely to require the intensity of FOLFIRINOX, potentially allowing greater flexibility in treatment selection.
Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors.
The publication is available through the Caris website.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-npj-precision-oncology-study-showing-ai-guided-therapy-selection-is-predictive-of-longer-survival-in-patients-with-pancreatic-cancer-302861396.html
SOURCE Caris Life Sciences